donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
03933 UNITED LAB
4.710
-0.060-1.26%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Turnover
10.61% 9.7B 9.63% 4.72B 4.53% 8.77B 5.25% 4.3B
Operating income
10.61% 9.7B 9.63% 4.72B 4.53% 8.77B 5.25% 4.3B
Cost of sales
-10.59% -5.49B -4.65% -2.62B -4.09% -4.97B -5.81% -2.51B
Operating expenses
-10.59% -5.49B -4.65% -2.62B -4.09% -4.97B -5.81% -2.51B
Gross profit
10.64% 4.21B 16.57% 2.1B 5.11% 3.81B 4.47% 1.8B
Selling expenses
-10.08% -1.63B -5.92% -753.35M -0.42% -1.48B 6.73% -711.25M
Administrative expenses
5.89% -698.34M -2.79% -336.5M -0.18% -742M 9.12% -327.38M
Research and development expenses
-- -- -24.83% -203.17M -- -- -37.28% -162.76M
Impairment and provision
-349.93% -296.56M -5210.76% -105.58M -761.03% -65.91M 80.03% -1.99M
-Other impairment is provision
-349.93% -296.56M -5210.76% -105.58M -761.03% -65.91M 80.03% -1.99M
Special items of operating profit
-134.79% -319.82M -30.12% 57.29M 48.7% -136.22M 78.38% 81.98M
Operating profit
-8.37% 1.26B 11.52% 754.57M 11.81% 1.38B 60.21% 676.6M
Financing cost
66.77% -60.23M 74.53% -32.36M 35.45% -181.27M 7.91% -127.05M
Special items of earning before tax
-- -- -- -- -185.71% -314.61M -526.86% -223.66M
Earning before tax
36.3% 1.2B 121.61% 722.2M 4.83% 882.33M -3.22% 325.9M
Tax
-17.44% -213.06M 20.7% -97.59M 9.24% -181.42M -201.34% -123.06M
After-tax profit from continuing operations
41.18% 989.59M 207.94% 624.62M 9.22% 700.92M -31.46% 202.84M
Earning after tax
41.18% 989.59M 207.94% 624.62M 9.22% 700.92M -31.46% 202.84M
Minority profit
171.8% 1.49M -- 1.54M -- -2.07M -- --
Profit attributable to shareholders
40.56% 988.1M 207.18% 623.08M 9.54% 702.99M -31.46% 202.84M
Basic earnings per share
34.89% 0.537 182.87% 0.3386 1.71% 0.3981 -33.68% 0.1197
Diluted earnings per share
34.89% 0.537 182.87% 0.3386 1.71% 0.3981 -33.68% 0.1197
Currency Unit
CNYCNYCNYCNY
Accounting Standards
HKASHKASHKASHKAS
Audit Opinions
Unqualified Opinion--Unqualified Opinion--
Auditor
Deloitte Guan Huang Chen Fang Accountants--Deloitte Guan Huang Chen Fang Accountants--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Federal Pharmaceutical International Holdings Co., Ltd. is an investment holding company, mainly engaged in the sale of intermediate products, API and preparation products. The company operates through three business units. The intermediate department is engaged in the business of selling intermediate products. The API Department is engaged in the business of selling APIs. The preparation products Department is engaged in the sales of antibiotic preparation products, non-antibiotic preparation products and hollow capsules. The company, through its subsidiaries, is also engaged in the manufacture and sale of organic fertilizers.
CEO: Haishan Cai
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...